Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Forte Bio Announces Third Quarter 2023 Results and Provides Business Update
Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2023 results and provided a business update.
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update